key: cord-1049600-3h4rsic6
authors: Brown, Li-An K.; Moran, Ed; Goodman, Anna; Baxendale, Helen; Bermingham, William; Buckland, Matthew; AbdulKhaliq, Iman; Jarvis, Hannah; Hunter, Michael; Karanam, Surendra; Patel, Aisha; Jenkins, Megan; Robbins, Alexander; Khan, Sujoy; Simpson, Thomas; Jolles, Stephen; Underwood, Jonathan; Savic, Sinisa; Richter, Alex; Shields, Adrian; Brown, Michael; Lowe, David M.
title: Treatment of chronic or relapsing COVID-19 in immunodeficiency
date: 2021-11-12
journal: J Allergy Clin Immunol
DOI: 10.1016/j.jaci.2021.10.031
sha: 6ca13d482126522cbd49ba64bd44eb24e54289b6
doc_id: 1049600
cord_uid: 3h4rsic6

Background Patients with some types of immunodeficiency can suffer chronic or relapsing infection with SARS-CoV-2. This leads to morbidity and mortality, infection control challenges and the risk of evolution of novel viral variants. Optimal treatment for chronic COVID-19 is unknown. Objective To characterise a cohort of patients with chronic or relapsing COVID-19 disease and to record treatment response. Methods We conducted a UK physician survey to collect data on underlying diagnosis and demographics, clinical features and treatment response of immune deficient patients with chronic (at least 21 days) or relapsing (at least two episodes) of COVID-19. Results We identified 31 cases with a median age of 49 years. Underlying immune deficiency was characterised by antibody deficiency with absent or profoundly reduced peripheral B cells; prior anti-CD20 therapy and X-linked agammaglobulinemia were most common. Clinical features of COVID-19 were similar to the general population, but the median duration of symptomatic disease was 64 days (maximum 300 days) and individual patients experienced up to five episodes of illness. Remdesivir monotherapy (including when given for prolonged courses up to 20 days) was associated with sustained viral clearance in 7/23 (30.4%) clinical episodes whereas the combination of remdesivir with convalescent plasma or anti-SARS-CoV-2 monoclonal antibodies resulted in viral clearance in 13/14 (92.8%) episodes. Patients receiving no therapy did not clear SARS-CoV-2. Conclusions COVID-19 can present as a chronic or relapsing disease in patients with antibody deficiency. Remdesivir monotherapy is frequently associated with treatment failure, but the combination of remdesivir with antibody-based therapeutics holds promise.

Severe acute respiratory syndrome coronavirus-2 J o u r n a l P r e -p r o o f

Antibody-deficient patients suffer chronic infection with certain viruses, 1,2 and SARS-CoV-2 infection can also become persistent or relapsing. [3] [4] [5] [6] [7] [8] This risks chronic ill health, permanent lung disease, intrahost evolution of viral variants, 9 and social isolation. Optimal treatment is not yet established.

We conducted a UK physician survey collecting anonymised data on immunosuppressed adults with prolonged or relapsing COVID-19 (≥21 days' duration and/or ≥2 episodes of clinical illness). The survey was sent to all immunologists in the UK via a professional network, to infectious diseases and other specialists via the COVID-19 Therapeutics Advice & Support Group (CTAG) and to individual clinicians who were known to have managed patients in the target group. Data were only derived from information collected as part of routine clinical care and were provided in fully anonymised form.

31 responses were received ( Table 1 ). The median duration of symptomatic disease was 62 days (maximum 300 days); the median time between first recorded and most recent positive SARS-CoV-2 PCR was 48 days (>200 days in 4 patients).

The median age was 49 years. 17/31 (54.8%) had a primary immunodeficiency causing hypogammaglobulinaemia, with a high frequency of X-linked agammaglobulinemia (XLA), and 14/31 (45.2%) had secondary immunodeficiency, mostly previous anti-CD20 treatment. Accordingly, patients demonstrated a striking absence of peripheral blood B cells with a median count of zero; the maximum B cell count recorded was 0.056 x 10 9 /L with a maximum 3% of blood lymphocytes. In contrast, T cell counts were relatively well preserved (Table 1) . Immunoglobulin G trough levels were within an acceptable range for those on replacement therapy prior to COVID-19 diagnosis but low in those not previously on treatment. IgA and IgM concentrations were generally very low or absent.

Patients with XLA had a confirmed genetic diagnosis or absent Bruton tyrosine kinase (Btk) expression and one patient had confirmed Wiskott-Aldrich syndrome. Other patients with primary immunodeficiencies, including those with CVID, did not have a genetic diagnosis. Causes of secondary antibody deficiency are listed in Table 1 We recorded virological outcome per patient according to the maximal antiviral treatment received ( Figure 1A ), defined as remdesivir or antibody-based therapy (convalescent plasma and SARS-CoV-2specific monoclonal antibodies). Among 20 patients who cleared infection (median symptom duration 51.5 days): 13 received a combination of remdesivir plus antibody-based therapy (8 REGN-COV2, 5 convalescent plasma); 5 remdesivir monotherapy ≤10 days per course; 2 remdesivir monotherapy for > 10 days in a single course. Viral clearance was delayed in 3 cases treated with remdesivir monotherapy and 1 case treated with combination therapy. Among 11 patients who did not clear the infection (median symptom duration 70 days): 1 received combination therapy (remdesivir plus convalescent plasma); 6 remdesivir monotherapy ≤10 days; 1 remdesivir monotherapy for >10 days; 3 no antiviral treatment (p=0.006 by chi-square test for treatment difference between the groups). Via logistic regression controlling for age, sex and underlying diagnosis, the odds ratio of clearing infection with combination therapy versus remdesivir monotherapy was 23.1 (95% CI 1.3-424.9, p=0.035).

The patient who received combination therapy but failed to clear SARS-CoV-2 died after a monophasic illness lasting 23 days. The patient with delayed clearance received sequential therapy (remdesivir followed three weeks later by REGN-COV2), while other patients received the therapies contemporaneously.

We also analysed each of the 62 episodes of clinical COVID-19 illness ( Figure 1B ). We classified outcomes as unfavourable (persistent PCR positivity, clinical relapse, death) or viral clearance. Episodes with successful outcome are described above. Among 42 episodes with unfavourable outcome, 3 had no treatment details, 22 received no treatment, 15 remdesivir monotherapy ≤10 days, 1 remdesivir monotherapy for >10 days, and 1 combination therapy (as above); p<0.0001 by chi-square test for difference in outcome according to treatment received. Overall, 16/23 (69.6%) episodes treated with remdesivir monotherapy had an unfavourable outcome and 7/23 (30.4%) had viral clearance (delayed in three instances).

We also analysed clinical outcomes (overall clinical improvement, reduction in fever, reduction in serum C-reactive protein (CRP), reduction in oxygen requirement and discharge from hospital) per episode of illness (Supplementary Figure 1) . Many untreated episodes demonstrated some spontaneous improvement with discharge from hospital. However, fever and CRP often did not improve significantly. In contrast, for the vast majority of episodes treated with remdesivir or combination therapy (and where outcome data were available), there was improvement in fever, CRP and oxygen requirement, regardless of sustained viral clearance.

Immunosuppressive and immunomodulatory therapeutic approaches were tried in some patients. The most commonly prescribed treatment was dexamethasone or other corticosteroids, in 25/62 episodes (40.3%). Other treatments given were tocilizumab (3 episodes), anakinra (4 episodes), and IVIG (2 episodes). One patient additionally received inhaled tissue plasminogen activator. 6/62 (9.7%) clinical episodes were treated with immunosuppressive or immunomodulatory treatments without antiviral treatments; none of these resulted in viral clearance.

Overall, our survey of 31 antibody-deficient patients with COVID-19 has demonstrated a high burden of morbidity among this population and has highlighted that combination therapy with antivirals and antibody-based therapeutics is associated with the highest rate of viral clearance.

Compared to the general hospitalised population with COVID-19, our cohort tended to be younger and have less comorbidity 10 . The underlying immunodeficiency was almost invariably characterised by antibody deficiency including a high frequency of patients with X-linked agammaglobulinemia or prior anti-CD20 treatment: there was a striking absence or profound reduction in peripheral blood B cells across this cohort. Some patients in the cohort may have broader immune compromise including impaired T cell function, while monocyte function may be impaired in XLA, but the composition of this cohort nevertheless implicates B cells and antibodies as key immunological components required to clear SARS-CoV-2 infection.

There are several case reports of COVID-19 outcomes amongst antibody-deficient patients who have not received any specific proven antiviral therapy. Some have died 7,11 , but full recovery from mild illness 11, 12 and even severe disease with intubation 13, 14 has been reported in others.

In our surveyed patients, all untreated episodes had an unfavourable outcome of persistent PCR positivity and/or clinical relapse or death, although patients were only included in analysis if they had at least 21 days duration of symptoms and/or at least 2 episodes of clinical illness, which introduced a deliberate bias. Thus, while the published literature confirms that mild disease and spontaneous clearance of infection is a possible outcome in these groups of patients, chronic or relapsing disease 15 may well require specific therapy.

We found that a significantly higher proportion of patients had sustained clearance of SARS-CoV-2 after treatment with combination antiviral therapy (remdesivir plus antibody therapy, 13/14 (92.8%) achieved viral clearance) as compared to those treated with remdesivir alone (7/14 (50%) achieved viral clearance, often delayed), or with no specific treatment (0/3 achieved viral clearance).

Remdesivir monotherapy was given in 23 out of 62 clinical episodes in our surveyed patients and led to mixed outcomes; 16/23 episodes (69.6%) had an unfavourable outcome and 7/23 (30.4%) had viral clearance (delayed in three cases). However, remdesivir treatment generally led to an improvement in physiological parameters (fever, CRP and oxygen requirement) even if there was no viral clearance and/or a subsequent clinical relapse. Remdesivir may therefore have utility in unwell patients where there is no access to antibody-based therapies (although there may be a risk of selecting resistant viral sub-populations).

Failure to clear SARS-CoV-2 from antibody-deficient patients after remdesivir monotherapy has been reported in similar patients. 3, 5, 8, [16] [17] [18] However, a good response to remdesivir in antibody deficiency has been documented in other cases. 11, 19 Notably, remdesivir was often used outside of UK commissioning guidelines at the time in the patients in our cohort (i.e. beyond 10 days from symptom onset) and some were treated with prolonged courses up to 20 days' duration. As numbers were small, it is unclear whether this approach was more successful than 'standard' (as per clinical trials) courses up to 10 days' duration.

None of the patients included in our survey had received anti-SARS-CoV-2 antibody therapy alone. However, successful treatment with convalescent plasma alone has been described [4] [5] [6] [7] 19 including in 16 out of 17 B-cell depleted patients with chronic COVID-19, 16 8 out of 14 treated patients with secondary immunodeficiency, 20 and two patients with CVID and severe COVID-19. 21, 22 In contrast, monotherapy with convalescent plasma 19 or REGN-COV-2 8 was not successful in other cases.

Combination therapy with remdesivir and convalescent plasma or REGN-COV2 was generally a successful strategy in our surveyed patients. Successful outcomes with combination therapy have also been demonstrated in other similar patients 17-19,23,24 but this strategy failed in a patient with CVID who died at day 30 despite maximal therapy, 25 similar to a patient in our cohort.

In summary, in predominantly B cell and antibody-deficient patients with chronic or relapsing COVID-19, a significantly higher proportion of patients experienced sustained clearance of SARS-CoV-2 after treatment with remdesivir plus antibody therapy compared to remdesivir alone or no specific treatment. Currently, access to antibody-based treatments is challenging in many parts of the world, while access to any antiviral therapeutic is often restricted to those with early disease. Although appropriate for immunocompetent individuals, this approach does not address the needs of chronically infected patients. Indeed, many of the patients reported here were only treated as part of large, open-label trials where they could equally have been randomised to standard of care, or due to favourable decisions from pharmaceutical companies' compassionate use committees.

From both a clinical and public health perspective, we encourage improved access to treatment for these patients via protocols or studies with careful monitoring for outcome. Well conducted observational studies can provide vital data on rare patients such as these and may even be preferable to large, randomised controlled studies where recruitment would be challenging and use of placebos can present ethical issues. 

Mid and South Essex NHS Foundation Trust

A comprehensive characterization of chronic norovirus infection in immunodeficient hosts

Recurrent and persistent respiratory tract viral infections in patients with primary hypogammaglobulinemia

Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report

Rapid recovery of a SARS-CoV-2-infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma

Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma

Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer

Severe COVID-19 in Patients with B Cell Alymphocytosis and Response to Convalescent Plasma Therapy

Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host

Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations

Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study

A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia

Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover

Positive outcome in a patient with coronavirus disease 2019 and common variable immunodeficiency after intravenous immunoglobulin

The clinical observation of a patient with common variable immunodeficiency diagnosed as having coronavirus disease 2019

Long-Term Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectiousness Among Three Immunocompromised Patients: From Prolonged Viral Shedding to SARS-CoV-2 Superinfection

Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19

Sustained response after remdesivir and convalescent plasma therapy in a B-cell depleted patient with protracted COVID-19

Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy

Coronavirus disease 2019 in patients with inborn errors of immunity: An international study

Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19

Report: Convalescent Plasma, a Targeted Therapy for Patients with CVID and Severe COVID-19

Rapid clinical recovery of a SARS-CoV-2 infected common variable immunodeficiency patient following the infusion of COVID-19 convalescent plasma

Infection Treated with Remdesivir and Convalescent Plasma

Emerging RNA-Dependent RNA Polymerase Mutation in a Remdesivir-Treated B-cell Immunodeficient Patient With Protracted Coronavirus Disease

A fatal case of coronavirus disease 2019 in a patient with common variable immunodeficiency

Not tested 9On immunoglobulin replacement therapy at time of survey

No -patient died 3No -does not meet NHS England criteria 6No -experienced significant side effects 1 ◊ Diabetes mellitus, hypertension, ischaemic heart disease, other heart diseases (e.g. arrhythmia, valvular heart disease), asthma, chronic obstructive pulmonary disease, other chronic respiratory disease * In some instances, details were not provided for all episodes of illness (for example, those managed in the community) and this figure is therefore likely to be an underestimate. † All patients had received antibody-based therapies ‡ Follicular lymphoma (3)